Alexion’s Soliris wows in rare disease PhIII trial, opening up a new franchise worth $500M-$700M
Three years after it launched, Alexion $ALXN says that the Phase III study of its cash cow Soliris for rare cases of relapsing neuromyelitis optica spectrum disorder scored a clear and convincing win, setting up some near term applications that one prominent analyst expects could be worth up to $700 million a year in new money.
The disease, NMOSD, is often confused with multiple sclerosis as the immune system attacks healthy tissue in the spine and eyes, responsible for blinding and sometimes killing patients. The drug inhibits the complement system, which investigators believe plays a key role in the autoimmune disorder.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.